Get the Stockscreener App
36.49
6.11%
2.10
Vtv Therapeutics Inc stock is traded at $36.49, with a volume of 30,353.
It is up +6.11% in the last 24 hours and up +6.95% over the past month.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
See More
Previous Close:
$34.39
Open:
$33.75
24h Volume:
30,353
Relative Volume:
1.65
Market Cap:
$143.70M
Revenue:
$17,000
Net Income/Loss:
$-23.87M
P/E Ratio:
-11.70
EPS:
-3.12
Net Cash Flow:
$-22.03M
1W Performance:
+17.67%
1M Performance:
+6.95%
6M Performance:
+151.83%
1Y Performance:
+102.72%
1-Day Range:
$31.98
$37.98
1-Week Range:
$28.84
$37.98
52-Week Range:
$14.00
$44.00
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Name
Vtv Therapeutics Inc
Sector
Industry
Phone
336-841-0300
Address
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
36.49 | 135.43M | 17,000 | -23.87M | -22.03M | -3.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Jan-05-26 | Initiated | TD Cowen | Buy |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| May-30-19 | Initiated | H.C. Wainwright | Buy |
| Apr-10-18 | Downgrade | Stifel | Buy → Hold |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Initiated | Northland Capital | Outperform |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Sep-04-15 | Initiated | Canaccord Genuity | Buy |
| Aug-24-15 | Initiated | Piper Jaffray | Overweight |
| Aug-24-15 | Initiated | Stifel | Buy |
View All
Vtv Therapeutics Inc Stock (VTVT) Latest News
Aug Retail: Does vTv Therapeutics Inc have strong fundamentalsEarnings Overview Report & Stepwise Swing Trade Plans - baoquankhu1.vn
(VTVT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Q1 EPS Forecast for vTv Therapeutics Increased by Analyst - Defense World
HC Wainwright Boosts Earnings Estimates for vTv Therapeutics - MarketBeat
Will vTv Therapeutics Inc outperform the market in YEARQuarterly Trade Report & Stepwise Trade Signal Guides - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: vTv Therapeutics (VTVT), Acumen Pharmaceuticals (ABOS) - The Globe and Mail
vTv Therapeutics expands HPP737 license agreement with Newsoara Biopharma By Investing.com - Investing.com India
vTv Therapeutics expands HPP737 license agreement with Newsoara Biopharma - Investing.com
vTv Therapeutics Expands Global HPP737 Rights with Newsoara - TipRanks
vTv Therapeutics Signs License Agreement Amendment With Newsoara Biopharma - TradingView
vTv expands Newsoara license deal for PDE4 inhibitor to global rights - Investing.com India
VTVT Expands Global Rights Agreement for PDE4 Inhibitor - GuruFocus
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737 - GlobeNewswire
Analysts Set vTv Therapeutics Inc. (NASDAQ:VTVT) Price Target at $55.25 - Defense World
VIX Spike: Is vTv Therapeutics Inc likely to announce a buybackMarket Volume Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
vTv Therapeutics Inc. (NASDAQ:VTVT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Published on: 2026-01-29 06:19:41 - baoquankhu1.vn
VTVT: BTIG Raises Price Target to $49.00, Maintains Buy Rating | - GuruFocus
How (VTVT) Movements Inform Risk Allocation Models - Stock Traders Daily
vTv Therapeutics (NASDAQ:VTVT) Upgraded to Strong-Buy at Roth Mkm - MarketBeat
This MasTec Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Roth Capital Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation - Nasdaq
Roth/MKM initiates coverage on vTv Therapeutics stock with Buy rating - Investing.com Canada
Roth Capital Initiates Coverage on VTVT with a 'Buy' Rating | VT - GuruFocus
Buyout Rumor: Does vTv Therapeutics Inc have declining or rising EPSWeekly Gains Summary & Verified Momentum Stock Alerts - baoquankhu1.vn
Published on: 2026-01-19 16:04:02 - baoquankhu1.vn
vTv Therapeutics (VTVT) upgraded to buy: Here's what you should know - MSN
Meme Stocks: Should I hold or sell Aethlon Medical Inc nowJuly 2025 News Drivers & Technical Buy Zone Confirmation - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Stop Loss: Can IRDM navigate macro headwindsWeekly Market Outlook & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Rises By 62.3% - MarketBeat
Trading Systems Reacting to (VTVT) Volatility - Stock Traders Daily
vTv Therapeutics (VTVT) Price Target Increased by 16.19% to 48.20 - Nasdaq
Alzheimer’s Disease Market in the 7MM is projected to reach USD 34 Billion by 2034, analyses DelveInsight - The Globe and Mail
Market Pulse: What margin trends mean for vTv Therapeutics Inc stockJuly 2025 Earnings & Fast Entry Momentum Trade Alerts - Bộ Nội Vụ
Analysis Recap: Will vTv Therapeutics Inc face regulatory challengesWeekly Trade Report & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
How vTv Therapeutics Inc. stock reacts to global recession fearsTrade Ideas & Community Shared Stock Ideas - Улправда
Smart Money: Can vTv Therapeutics Inc. (5VT0) stock attract analyst upgrades2025 Growth vs Value & Target Return Focused Stock Picks - ulpravda.ru
How vTv Therapeutics Inc. (5VT0) stock reacts to new regulationsRate Hike & Free Accurate Trade Setup Notifications - Улправда
Why institutional investors increase stakes in vTv Therapeutics Inc. (5VT0) stockWeekly Risk Summary & Daily Technical Stock Forecast Reports - Улправда
P 500 performance this yearJuly 2025 Levels & Real-Time Market Trend Scan - Улправда
Momentum Shift: How vTv Therapeutics Inc. (5VT0) stock reacts to new regulations2025 AllTime Highs & Daily Stock Trend Reports - Улправда
Should I hold or sell vTv Therapeutics Inc. stock in 2025July 2025 Final Week & Growth Focused Stock Pick Reports - Улправда
Brokerages Set vTv Therapeutics Inc. (NASDAQ:VTVT) PT at $51.33 - Defense World
Is vTv Therapeutics Inc. stock supported by innovation pipeline2026 world cup usa national team group stage goalkeepers build up play knockout prediction statistical analysis - Улправда
vTv Therapeutics (NASDAQ:VTVT) Now Covered by Analysts at TD Cowen - Defense World
TD Cowen Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation - Nasdaq
An Alzheimer’s Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here? - Yahoo Finance
vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
VTVT: TD Cowen Initiates Coverage with a Buy Rating and $67 Pric - GuruFocus
This vTv Therapeutics Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Vtv Therapeutics Inc Stock (VTVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):